Hims & Hers Stock Soars on Strategic Pivot with Novo Nordisk

Hims & Hers settles patent litigation, will now sell Novo Nordisk's Ozempic and Wegovy. The telehealth firm forecasts $2.7-$2.9B revenue for 2026.

Shares of telehealth company Hims & Hers Health, Inc. surged approximately 57% last week, closing Friday at $24.77. This dramatic move follows a pivotal legal settlement and strategic shift in its weight management business, marking a fundamental change in its operational model.

A Strategic Settlement Reshapes the Business

The company has resolved its patent litigation with pharmaceutical giant Novo Nordisk. The agreement represents a compromise for both parties: Novo Nordisk will withdraw its lawsuit, while Hims & Hers will cease selling its own compounded versions of GLP-1 medications. In a significant strategic pivot, the telehealth platform will now become an authorized distributor, selling Novo Nordisk's FDA-approved brand-name drugs, Ozempic and Wegovy, directly to consumers.

While this shift may pressure profit margins as the company transitions from a proprietary product marketer to a reseller, market analysts view the long-term strategic benefits as substantial. These include a reduction in legal risk, improved access to insurance reimbursements, and enhanced consumer trust by offering established pharmaceutical products.

Financial Performance and Growth Trajectory

Hims & Hers continues to demonstrate robust growth. Its subscriber base surpassed 2.5 million active users by the end of 2025, with over 65% enrolled in personalized treatment plans. For the 2026 fiscal year, management has provided revenue guidance of $2.7 to $2.9 billion. This forecast follows 2025 revenue of $2.35 billion, representing a 59% year-over-year increase.

International expansion is a key growth driver. The acquisition of Australian telehealth provider Eucalyptus has provided entry into the Australian and Japanese markets. Although starting from a small base, the international segment saw remarkable growth of 400% in 2025, reaching $134 million.

Market Sentiment and Future Challenges

The financial community has responded favorably to the company's new direction. Needham raised its price target to $30, while Citi set a target of $24. The current average analyst price target stands at $30.65. In a notable show of confidence, Clear Street Group recently acquired a 0.68% stake in the company for approximately $87 million. Furthermore, Hims & Hers has authorized a new $250 million share repurchase program.

Despite the recent rally, the stock remains about 54% below its six-month high, underscoring the depth of its previous decline. A key metric to watch will be customer acquisition costs, which were $929 per user in 2024 and continue to challenge profitability. The effectiveness of the new distribution partnership with Novo Nordisk in potentially lowering these costs over the medium term will become clearer when the company reports its quarterly results for the first half of 2026.